Document:

Exhibit

Exhibit 10.31

October 4, 2017

Thomas Carson
BY HAND DELIVERY

Dear Tom, 
This is to confirm the parameters of your retirement from TiVo Corporation or one of its subsidiaries (collectively, “TiVo” or the “Company”), which was publicly announced by the Company on May 24, 2017 and the orderly continuation of your duties in connection with the Board of Directors (the “Board”) finding your successor.  
As previously discussed, you will continue in your role as President and CEO and a member of the Board of TiVo until the date on which a new CEO commences employment (the “Transition Date”).  As of the Transition Date, you also will cease being a member of the Board of Directors and you will no longer be responsible for your current responsibilities as CEO and you will no longer have your current team reporting to you.   From the Transition Date through April 6, 2018 (the “Termination Date”, and such period being referred to as the “Transition Period”), your new title will be Strategic Advisor, reporting to the Chairman of the Board of the Company.  During the Transition Period, you agree to support the orderly transition of responsibilities for Company operations to the new CEO and help advise the Board as requested.  
During the Transition Period, your base salary of $625,000 and 2017 Senior Executive Company Incentive Plan bonus eligibility of 100% of base salary remain unchanged.  In addition, all issued unvested equity awards will remain eligible to vest in accordance with their terms during the Transition Period.  You will receive standard health, welfare and other employee benefits during the Transition Period as any other full-time employee; provided, however, you shall not be eligible to participate in the 2018 Senior Executive Company Incentive Plan.  During the Transition Period and the Salary Continuation period (as defined below), your position will be located in the Wayne, Pennsylvania office and/or remotely from your home in Pennsylvania, provided, however, that occasional travel on business related activities may be needed.   The Company shall reimburse you for all reasonable business-related expenses and business travel expenses incurred during the Transition Period and the Salary Continuation Period in accordance with the Company’s travel and expense reimbursement policy (and the parameters for CEO-level employees contained in the Company’s travel policy in effect as of the Transition Date shall apply during both the Transition Period and the Salary Continuation Period). 
Until the earliest to occur of (i) the date on which your employment is terminated through no fault of your own (and other than due to death or disability) and (ii) the Transition Date, you shall continue to be entitled to all rights and benefits for which you are eligible under the terms and conditions of the Amended and Restated Executive Severance and Arbitration Agreement (the “Executive Agreement”) made and entered into as of December 14, 2011 by and between you and the Company, after which time no payments shall be made pursuant to the Executive Agreement but the remainder of the Executive Agreement shall remain in effect in accordance with its terms.
Following the end of the Transition Period, in exchange for (a) signing a separation agreement and release of claims against the Company in a form acceptable to the Company and allowing such release to take effect within the sixty (60) day period following the Termination Date and (b) continuing to assist the Company during the Salary Continuation period (as defined below) on matters of historical knowledge, including but not limited to existing or future litigation about which you have relevant knowledge, you will be offered the following severance benefits: 
		
	(i)
	An amount equal to twelve months of base salary ($625,000), less all applicable withholdings and deductions, paid over such twelve-month period on the schedule and subject to the conditions described in Section 1(h) of the Executive Agreement (the “Salary Continuation”).

		
	(ii)
	A payment of $625,000, which is equal to 100% of your annual target bonus (assuming full performance, but no over-performance, of targets, and for clarity excluding any discretionary bonuses), payable in a lump-sum, less applicable deductions and withholdings, on the 60th day following the Termination Date.  For the avoidance of doubt, this reference to a bonus amount is solely as a proxy for calculating the severance payment and is not a substitute for your actual bonus, if any, under the 2017 Senior Executive Company Incentive Plan.

		
	(iii)
	Acceleration of the vesting of Stock Awards (as defined in Section 3 of the Executive Agreement), other than Performance-Based Vesting Shares (as defined in Section 3 of the Executive Agreement), held by you as of the Termination Date as to the number of shares that would have vested in accordance with the applicable vesting 

schedule as if you had been in service for an additional twelve months from the Termination Date (without giving effect to any Change in Control that may occur following the Transition Date).  Vested stock options may be exercised for a period of twelve (12) months following the date of your separation from service, but only to the extent it was exercisable on such separation date (after taking into account any acceleration).
		
	(iv)
	Welfare Benefits in accordance with Section 2(a) through 2(c) of the Executive Agreement.  For avoidance of doubt, the Company shall not provide the outplacement assistance benefit reimbursement contained in Section 2(d) of the Executive Agreement.

		
	(v)
	The Company’s directors’ and officers’ liability insurance policy shall continue to insure you after the Transition Period against insurable events which occurred while you were a director or officer of TiVo Corporation or its subsidiaries.  In addition, your Indemnification Agreement dated May 2, 2008 shall also continue with respect to claims arising out of your employment with the Company as provided under such agreement.     

If your employment is terminated through no fault of your own (and other than due to death or disability) prior to the end of the Transition Period, you shall receive, as applicable (i) your base salary and all other accrued amounts through the termination date and (ii) subject to your execution, delivery and non-revocation of an effective release of all claims against the Company within the sixty (60) day period following the date of your separation from service, the following:
		
	(a)
	in a lump sum, on the 60th day following the date of your separation from service, the remainder of your base salary amount for the Transition Period, less any amounts already paid through the date of your separation from service; and

		
	(b)
	all of the severance benefits listed in sections (i)-(v) above.

Sincerely,

James Meyer
Chairman of the Board

	
				
	Agreed & Accepted:  
	 
	 
	 

	 
	Thomas Carson
	 
	            DateExhibit

Confidential Treatment Requested by AdvanSix Inc.

Exhibit 10.28
 
SEVENTH AMENDMENT
TO AMENDED AND RESTATED
CAPROLACTAM AND POLYMER SUPPLY AGREEMENT

THIS SEVENTH AMENDMENT TO AMENDED AND RESTATED CAPROLACTAM AND POLYMER SUPPLY AGREEMENT (this “Amendment”) is entered into as of February 22, 2018, by and between AdvanSix Resins & Chemicals LLC (“Seller”), and Shaw Industries Group, Inc., a Georgia corporation (“Buyer”).
Recitals

WHEREAS, on April 1, 2013, Seller and Buyer entered into that certain Amended and Restated Caprolactam and Polymer Supply Agreement (as amended, the “Agreement”);
WHEREAS, the parties desire to amend certain provisions of the Agreement; and
WHEREAS, capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.
Agreement

NOW, THEREFORE, in consideration of the mutual terms, conditions and other agreements set forth herein, the parties, intending to be legally bound hereby, agree as follows:

1.    Section 1.9 of the Agreement is deleted in its entirety, and inserted in lieu thereof is a new Section 1.9, as follows:

“1.9    [***] Volume Adjustment.  Notwithstanding Article 1.2 of this Agreement, between [***], through [***], (i) the annual Minimum Volume shall be [***] ([***]) pounds of Product, and (ii) the annual Maximum Volume shall be [***] ([***]) pounds of Product.  Notwithstanding Article 1.2(a) of the Agreement, the minimum annual volume for Polymer shall be [***] pounds ([***]) and the maximum annual volume for Polymer shall be [***] pounds ([***]) from [***], through [***].”
2.    Section 1.4 of the Agreement is deleted in its entirety, and inserted in lieu is a new Section 1.4, as follows:

“1.4   Further Volume Adjustments.  Notwithstanding any of the foregoing contained in this Agreement, overall volume ranges of Product to be purchased by the Buyer during the periods described in the Agreement may be amended, with respect to any [***] ([***])-month period, to reflect an increase or decrease in the annualized rate in an amount not to exceed [***] ([***]) pounds, with [***] ([***]) days prior written notice by the Buyer to Seller; provided, however, that under no circumstance shall the Buyer be entitled to purchase Product at an annualized rate of more than [***] ([***]) pounds.  In the event of any such amendment, notwithstanding the provisions of the Agreement, such range of annualized rate of Product to be purchased by the Buyer established by such an amendment shall remain in effect until such time, if any, that the Buyer shall again exercise its rights under and subject to this Article 1.4 to further increase or decrease in the minimum and/or maximum 

Confidential Treatment Requested by AdvanSix Inc.

annualized rate of Product to be purchased by the Buyer then-in-effect in an amount not to exceed [***] ([***]) pounds.”
3.    Section 2.1 of the Agreement is deleted in its entirety, and inserted in lieu thereof is a new Section 2.1, as follows:

“2.1    Caprolactam Pricing.  The price for each pound of [***] Caprolactam shall be the sum of (x) [***] ($[***]) plus (y) the Caprolactam Index Amount (as defined in Schedule 2.1(I)), which, may be a positive or a negative amount, plus (z) the Caprolactam Adder Amount.  The Caprolactam Adder Amount shall be: (i) for the period of [***], through [***], [***] ($[***]) per pound of Product, (ii) for the period of [***], through [***], [***] ($[***]) per pound of Product, and (iii) for the period of [***], through the last day of the Term, [***] ($[***]) per pound of Product.”    
4.    Steam - Steam shall be redefined as the average actual dollars per [***] pounds of delivered steam for the previous [***], in US dollars, as reported by Seller.  Seller will provide a written [***] summary.

5.    All capitalized terms used, but not defined, herein shall have the meaning set forth in the Agreement.

6.    This Amendment may be executed in counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement.

7.    Except as expressly modified in this Amendment, the Agreement remains in full force and effect.  The Agreement and this Amendment together constitute the entire agreement between the Parties with respect to the subject matter hereof, and supersede all prior agreements or understandings between the Parties as to the subject matter hereof.

[The Remainder of this Page has been Intentionally Left Blank]

Confidential Treatment Requested by AdvanSix Inc.

IN WITNESS WHEREOF, the parties have executed this Seventh Amendment to Caprolactam and Polymer Supply Agreement as of the date first above written.

	
			
	ADVANSIX RESINS & CHEMICALS LLC
	 
	SHAW INDUSTRIES GROUP, INC.

	 
	 
	 

	 
	 
	 

	By: /s/ Erin Kane
	 
	By: /s/ David Morgan

	Erin Kane
	 
	David Morgan

	President
	 
	Executive Vice President Operations

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]